The BMJ has introduced a new policy requiring authors to share analytic codes from all studies and data from all trials. This policy aims to enhance transparency and ensure the reproducibility of research. The BMJ believes that sharing data and code is essential for the integrity of scientific research and for the benefit of patients and the public. Sharing data allows for scrutiny and re-analysis, which are crucial for good science. Code sharing, in particular, enables the evaluation of analytical decisions that may not be fully described in the methods section of a paper. The BMJ is committed to transparency and has previously required data sharing for drug and device trials. However, data sharing remains low, and authors face challenges such as time and effort, and concerns about unfair competition or misuse of data. From 1 May 2024, The BMJ will require authors of all submitted trials to post relevant trial data in an enduring, publicly accessible repository such as Vivli before publication. Authors of trials currently accepted for publication are encouraged to voluntarily adhere to this policy. A link to the trial data will be included in the data sharing statement on every research paper published in The BMJ. The BMJ also requires submission of relevant analytical code in a supplementary file that will be permanently accessible alongside each paper. The new policy applies to all research published by The BMJ, and a new code availability statement will be included in research papers. Other journals are also moving in this direction. The BMJ hopes that this policy will enhance transparency and scrutiny of medical research, putting the public good ahead of personal, academic, and corporate interests. The BMJ has no disqualifying financial ties to commercial companies, and the authors declare no other interests.The BMJ has introduced a new policy requiring authors to share analytic codes from all studies and data from all trials. This policy aims to enhance transparency and ensure the reproducibility of research. The BMJ believes that sharing data and code is essential for the integrity of scientific research and for the benefit of patients and the public. Sharing data allows for scrutiny and re-analysis, which are crucial for good science. Code sharing, in particular, enables the evaluation of analytical decisions that may not be fully described in the methods section of a paper. The BMJ is committed to transparency and has previously required data sharing for drug and device trials. However, data sharing remains low, and authors face challenges such as time and effort, and concerns about unfair competition or misuse of data. From 1 May 2024, The BMJ will require authors of all submitted trials to post relevant trial data in an enduring, publicly accessible repository such as Vivli before publication. Authors of trials currently accepted for publication are encouraged to voluntarily adhere to this policy. A link to the trial data will be included in the data sharing statement on every research paper published in The BMJ. The BMJ also requires submission of relevant analytical code in a supplementary file that will be permanently accessible alongside each paper. The new policy applies to all research published by The BMJ, and a new code availability statement will be included in research papers. Other journals are also moving in this direction. The BMJ hopes that this policy will enhance transparency and scrutiny of medical research, putting the public good ahead of personal, academic, and corporate interests. The BMJ has no disqualifying financial ties to commercial companies, and the authors declare no other interests.